Pure Global AI
NCST Document

NCST — Health research coordination policy, revised November 2012

National Policy Measures and Requirements for the Improvement of Health Research Co-ordination in Malawi — Revised Edition
MalawiNational Commission for Science and TechnologyClinical TrialsCurrentness under review
Document status

Currentness under review. Whether this instrument remains applicable is under review. Consult the later instruments and source context below before relying on it.

Document identity

National Policy Measures and Requirements for the Improvement of Health Research Co-ordination in Malawi — Revised Edition is published by National Commission for Science and Technology. This document is identified by its title; no separate official document code is recorded.

Instrument
Document
Full name
NCST — Health research coordination policy, revised November 2012
Category
Clinical Trials
Source links
Source publication
English
Linked source text; confirm the publisher, publication details and any later amendment or consolidated version.
Readable HTML
1 language version
Direct citations can link to a specific article or section by appending its fragment identifier.
Dates
Published
—
Effective
—
Readable full text

Open a language version

Each version has stable passage anchors for direct citations and highlighting. The readable text is generated from an authority source and does not replace the legally controlling publication.

About this regulation

National Policy Measures and Requirements for the Improvement of Health Research Co-ordination in Malawi — Revised Edition

Complete November 2012 revised policy: all 24 physical pages, twelve main sections, four footnotes, nine reference entries and original page images. It builds on the 2005 edition and cites sections 18 and 48 of the 2003 Act. The policy addresses human health/biomedical research, the historical NHSRC/COMREC jurisdictions, multicentre studies, study extension and institutional affiliation. Section 8 expressly concerns trials involving pharmaceutical products; its sequential ethics/drug-authority approval and amendment requirements are not generalized to independent medical devices. Four weeks concerns an optional pre-submission meeting request. Section 9 requires continuing review and addresses studies not started within one year; it supplies no general variation-review deadline. The 120 days from 1 March 2013 concerns the historical MOU transition, rather than the effective date of the entire policy. Original wording and references remain unchanged. The two-committee statement is not presented as a verified 2026 inventory. The 2005 predecessor, current committee recognition/SOPs, references and later implementation remain under review; excluded from default current-law discovery.

This document is identified by its title; no separate official document code is recorded. Always confirm the current consolidated text and transition provisions with the official source before filing.